Kirkland Advises Crown Laboratories on Close of Revance Acquisition
February 07, 2025
February 07, 2025
CHICAGO, Illinois, Feb. 7 -- Kirkland and Ellis, a law firm, issued the following news release:
Kirkland & Ellis advised Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, on the close of an agreement to purchase Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
Crown announced on February 5, 2025 that its . . .
Kirkland & Ellis advised Crown Laboratories, Inc., a privately held, global innovative leader in the skincare industry, on the close of an agreement to purchase Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
Crown announced on February 5, 2025 that its . . .